The 14 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 23.50, with a high estimate of 54.00 and a low estimate of 18.00. The median estimate represents a +106.32% increase from the last price of 11.39.
The current consensus among 15 polled investment analysts is to Hold stock in Nektar Therapeutics. This rating has held steady since November, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.81
Reporting Date Mar 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.